Casdatifan might have found its sweet spot, as part of a Cabometyx combo.
ApexOnco Front Page
Recent articles
Ibtrozi breezes through FDA review and gives Nuvation its first approval.
BDTX-1535 takes aim at PACC mutations and Tagrisso resistance.
What similarly acting projects are still unpartnered?
Response rates in a key group shrink from 62% to 39% as the company blames a “clerical error”.
After a conference lacking the wow factor, biotech winners and losers emerge.
Efficacy with Torl’s ADC looks in line, while toxicity with BNT211 still looms large.
What Relay managed with a combo Scorpion might be able to do with STX-478 monotherapy.